New hope for Tough-to-Treat lymphoma
NCT ID NCT06630091
Summary
This study is testing whether a new drug called golidocitinib can help control a rare and aggressive type of blood cancer called peripheral T cell lymphoma (PTCL). It will involve about 30 adults who have just been diagnosed and have not yet received treatment. Researchers want to see if giving golidocitinib by itself or alongside standard chemotherapy is safe and can keep the cancer from getting worse for at least two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.